Back to Search
Start Over
A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS.
- Source :
- Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p
- Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 02780232
- Volume :
- 39
- Database :
- Complementary Index
- Journal :
- Hematological Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 150945321
- Full Text :
- https://doi.org/10.1002/hon.123_2880